EPHA2 and irritable bowel syndrome: In the current study, we identified ALW-II-41-27, a novel ATP competitive EphA2 inhibitor, was capable of inhibiting intestinal motility in the mouse model mimicking diarrhea-predominant PI-IBS Symptoms.